Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) dropped 8% during trading on Thursday . The stock traded as low as $29.64 and last traded at $29.2940. Approximately 400,179 shares traded hands during trading, a decline of 80% from the average daily volume of 2,025,492 shares. The stock had previously closed at $31.85.
More Beam Therapeutics News
Here are the key news stories impacting Beam Therapeutics this week:
- Negative Sentiment: HC Wainwright reduced Beam Therapeutics’ earnings outlook across several future years, including FY2026 through FY2030, signaling a more cautious view on the company’s long-term profitability. Beam Therapeutics stock page
- Negative Sentiment: The firm also trimmed quarterly EPS estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027 and Q4 2027, which may weigh on sentiment near term. Beam Therapeutics stock page
- Neutral Sentiment: Beam Therapeutics recently reported better-than-expected quarterly results, but the company is still expected to post losses for the full year, so investors remain focused on its ability to narrow deficits over time. Beam Therapeutics stock page
Analyst Ratings Changes
BEAM has been the topic of several analyst reports. Wall Street Zen upgraded Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Sanford C. Bernstein reduced their price target on Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Wednesday. Canaccord Genuity Group initiated coverage on Beam Therapeutics in a report on Friday, February 20th. They set a “buy” rating and a $74.00 price target on the stock. Royal Bank Of Canada lifted their price target on Beam Therapeutics from $22.00 to $26.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beam Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.
Beam Therapeutics Stock Performance
The stock has a market capitalization of $2.87 billion, a PE ratio of -41.07 and a beta of 2.26. The firm’s fifty day moving average is $27.50 and its 200-day moving average is $27.17. The company has a current ratio of 16.99, a quick ratio of 16.99 and a debt-to-equity ratio of 0.09.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.12. Beam Therapeutics had a negative net margin of 39.66% and a negative return on equity of 29.00%. The business had revenue of $31.74 million during the quarter, compared to analysts’ expectations of $10.98 million. During the same period last year, the business earned ($1.23) earnings per share. The business’s revenue for the quarter was up 323.2% on a year-over-year basis. As a group, research analysts anticipate that Beam Therapeutics Inc. will post -4.23 earnings per share for the current year.
Insider Activity at Beam Therapeutics
In other Beam Therapeutics news, President Giuseppe Ciaramella sold 11,810 shares of Beam Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $290,289.80. Following the completion of the sale, the president directly owned 218,406 shares in the company, valued at $5,368,419.48. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Amy Simon sold 6,700 shares of Beam Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the sale, the insider owned 102,735 shares of the company’s stock, valued at approximately $2,525,226.30. This represents a 6.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,544 shares of company stock valued at $1,899,942 in the last ninety days. Insiders own 3.80% of the company’s stock.
Institutional Investors Weigh In On Beam Therapeutics
A number of institutional investors have recently made changes to their positions in BEAM. ARK Investment Management LLC increased its position in shares of Beam Therapeutics by 24.8% during the third quarter. ARK Investment Management LLC now owns 11,038,834 shares of the company’s stock valued at $267,913,000 after acquiring an additional 2,190,993 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new stake in shares of Beam Therapeutics during the third quarter valued at about $37,212,000. MWG Caph Ltd purchased a new stake in Beam Therapeutics during the fourth quarter worth about $35,119,000. State Street Corp increased its stake in Beam Therapeutics by 30.4% during the fourth quarter. State Street Corp now owns 5,228,529 shares of the company’s stock worth $144,935,000 after purchasing an additional 1,219,871 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Beam Therapeutics by 237.5% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock worth $40,419,000 after purchasing an additional 1,171,977 shares during the period. 99.68% of the stock is currently owned by institutional investors and hedge funds.
Beam Therapeutics Company Profile
Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.
Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.
Featured Stories
- Five stocks we like better than Beam Therapeutics
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
